リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients (本文)」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients (本文)

綿貫, 瑠璃奈 慶應義塾大学

2021.03.23

概要

Purpose: In adjuvant settings of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, anthracycline- based chemotherapy followed by taxane and trastuzumab is a standard regimen. Recent studies have reported the use of anthracycline-free adjuvant chemotherapy in selected HER2-positive breast cancer patients. We conducted a single-center retrospective study to identify the characteristics of HER2-positive breast cancer patients for whom anthracyclines can be safely omitted.

Methods: A total of 238 women were diagnosed with HER2-positive breast cancer and treated with neoadjuvant and/or adjuvant chemotherapy between January 1, 2008 and December 31, 2015 at Keio University Hospital. They were divided in two cohorts: an “anthracycline” cohort of 112 anthracycline-treated women and a “no anthracycline” cohort of 126 anthracycline-untreated women. Survival outcomes were estimated by Kaplan–Meier method.

Results: The 3-year disease-free survival rates in the no-anthracycline and anthracycline cohorts were 91.3% and 93.1%, respectively (P = 0.692). After using a statistical method with inverse probability of treatment weighting to minimize the selection bias, no significant differences were observed between the two cohorts (adjusted hazard ratio for disease-free sur- vival: 1.042; P = 0.909). Stratified by tumor size, no significant differences were observed between the two cohorts in the cT1N0 and cT2N0 subsets (P = 0.516 and P = 0.579, respectively). The recurrence rate was low among patients who achieved pathological complete response after receiving neoadjuvant chemotherapy with or without anthracyclines.

Conclusion: Our study suggests that anthracyclines can be safely omitted in selected patients with HER2-positive breast cancer, who have cT1N0 or cT2N0 and achieved pathological complete response after receiving neoadjuvant chemotherapy.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Seshadri R, Firgaira FA, Horsfall DJ et al (1993) Clinical signif- icance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11(10):1936–1942

2. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182

3. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712

4. Schramm A, De Gregorio N, Widschwendter P et al (2015) Tar- geted therapies in HER2-positive breast cancer—a systematic review. Breast Care (Basel) 10(3):173–178

5. Wuerstlein R, Harbeck N (2017) Neoadjuvant therapy for HER2-positive breast cancer. Rev Recent Clin Trials 12(2):81–92

6. Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752

7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672

8. Romond EH, Perez EA, Bryant J, et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684

9. Yu AF, Mukku RB, Verma S, et al (2017) Cardiac safety of non- anthracycline trastuzumab-based therapy for HER2-positive breast cancer. Breast Cancer Res Treat 166(1):241–247

10. Giordano SH, Lin YL, Kuo YF, et al (2012) Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30(18):2232–2239

11. Burstein HJ, Piccart-Gebhart MJ, Perez EA et al (2012) Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol 30(18):2179–2182

12. Morris PG, Hudis CA (2010) Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how wor-ried should we be? J Clin Oncol 28(21):3407–3410

13. Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2):134–141

14. Jones SE, Collea R, Paul D, et al (2013) Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-ampli- fied early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol 14(11):1121–1128

15. National Comprehensive Cancer Network website. http://www. nccn.org

16. Curtis LH, Hammill BG, Eisenstein EL et al (2007) Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 45(10 Supl 2):S103–S107

17. Cole SR, Hernan MA (2004) Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 75(1):45–49

18. Hernan MA, Robins JM (2006) Estimating causal effects from epi- demiological data. J Epidemiol Community Health 60(7):578–586

19. Austin PC (2009) Balance diagnostics for comparing the distribu- tion of baseline covariates between treatment groups in propen- sity-score matched samples. Stat Med 28(25):3083–3107

20. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458

21. von Minckwitz G, Procter M, de Azambuja E et al (2017) Adju- vant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122–131

22. Gianni L, Pienkowski T, Im YH et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast can- cer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17(6):791–800

23. Nakashoji A, Hayashida T, Yokoe T et al (2018) The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer. Cancer Treat Rev 62:9–17

24. Nagayama A, Hayashida T, Jinno H et al. Comparative effective- ness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis. J Natl Cancer Inst. 2014;106(9)

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る